DUBLIN--(BUSINESS WIRE)--The "Warts R&D Pipeline Analysis Report, Q4 2020" report has been added to ResearchAndMarkets.com's offering.
The Q4 Warts pipeline report is part of the 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Warts, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.
The comprehensive report on the indication presents Warts disease overview, Warts types, Warts symptoms, causes, and FDA/EMA approved treatment options.
The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Warts indication. The report presents near-term and long-term pipeline development trends and potential insights.
The report analyzes the development progress, current status, investments, partnerships, and other developments of 19 companies. Business profiles and contact details of the companies actively perusing Warts pipeline are assessed.
From the discovery stage of development to phase 3 development, all the potential pipeline drug candidates are analyzed in the report. Warts discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.
Scope and Coverage
- Warts pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates
- Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.
- Company-company partnerships, company-institute partnerships, and investment details of companies are included
- 19 companies are included including Aclaris Therapeutics Inc, Chengdu Institute of Biological Products Co Ltd, Cutanea Life Sciences Inc, Cytovation AS, Etna Biotech Srl, Feramda Ltd, G&E Corp, Genetic Immunity Inc, KinoPharma Inc, Laboratories Ojer Pharma SL, Maruho Co Ltd, Nielsen Biosciences Inc, Orgenesis Inc, Peritech Pharma, Phio Pharmaceuticals Corp, Shanghai Bovax Biotechnology Co Ltd, Veloce BioPharma LLC, Verrica Pharmaceuticals Inc, Xiamen Innovax Biotech Co Ltd,
- Disease overview, Pipeline trends, market analysis, and other developments
- Potential licensing/new business opportunities in Warts pipeline market
Highlights
- Global coverage of companies and pipeline agents
- 2020 Trends, market analysis, and developments
- Potential growth opportunities
- Comprehensive details of drug candidates
Reasons to Buy
- Drive pipeline research and commercial assessment
- Assess most promising drug candidates and stay ahead of the competition
- Strengthen your pipeline through identifying business expansion and acquisition opportunities
- Develop new candidates based on most focused targets and mechanism of actions
Key Topics Covered:
1. Table of Contents
2. Warts Pipeline Trends and Insights
2.1 Dominant Phase type of Warts Pipeline, 2020
2.2 Most focused Mechanism of Action in Warts Pipeline
2.3 Leading type of Route of Administration during 2020
2.4 Proportion of New Molecular Entities in Warts pipeline
2.5 Active Companies Developing Warts pipeline
3. Warts Disease Types, Symptoms, Causes, and Available Treatment Options
3.1 Disease Overview
3.2 Types
3.3 Symptoms
3.4 Approved Treatment Options
4. Warts Pipeline Company Trends and Insights- Business Profiles, Drug Candidates and Contacts
- Aclaris Therapeutics Inc
- Chengdu Institute of Biological Products Co Ltd
- Cutanea Life Sciences Inc
- Cytovation AS
- Etna Biotech Srl
- Feramda Ltd
- G&E Corp
- Genetic Immunity Inc
- KinoPharma Inc
- Laboratories Ojer Pharma SL
- Maruho Co Ltd
- Nielsen Biosciences Inc
- Orgenesis Inc
- Peritech Pharma
- Phio Pharmaceuticals Corp
- Shanghai Bovax Biotechnology Co Ltd
- Veloce BioPharma LLC
- Verrica Pharmaceuticals Inc
- Xiamen Innovax Biotech Co Ltd
5. Warts Pipeline Drug Profiles
5.1 Current Status of Drug and Vaccine Candidates
5.2 Drug Snapshot
5.2.1 Drug
5.2.2 Mechanism of Action
5.2.3 Phase
5.2.4 Co-Developer
5.2.5 Originator
5.2.6 Synonym
5.2.7 Route of Administration
5.2.8 Type of Molecule
5.2.9 Orphan Drug Status
5.2.10 New Molecular Entity
5.2.11 Area
5.3 Drug Details
5.4 Mechanism of Action
5.5 Licensing/Collaboration Agreements
5.6 Clinical Trial Details
6. Warts Pipeline Market News and Developments during 2020
7. Appendix
7.1 About the Publisher
7.2 Sources and Research Methodology
For more information about this report visit https://www.researchandmarkets.com/r/tz9ri9
